nach oben

Current Dermatology Reports

Erschienen in:

19.02.2018 | Psoriasis (Jaishin Wu, Section Editor)

Review Update on Topical Therapy for Psoriasis

verfasst von: Vermén M. Verallo-Rowell, Stephanie S. Katalbas, Mara Therese P. Evangelista, Johannes F. Dayrit

Erschienen in: Current Dermatology Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Studies show frequent usage but low adherence rates and poor satisfaction from topical therapy for psoriasis. These were attributed to low efficacy, inconvenience of application, and poor cosmetic quality for different body parts.

Recent Findings

Multicenter surveys on patients suggest a two-way holistic approach, where patients convey what bothers them most and doctors explain how products address specific concerns. New rapid response targeted topical agents, in cosmetically acceptable preparations, applied less often, are undergoing efficacy and safety studies, ideally on large populations up to 1 year or more. Until available, this review addresses gaps in knowledge on how to maximize effects of emollients, used alone, with physiologic lipids, or as base for active topical therapy.

Summary

Updates—on how psoriasis skin becomes itchy, red, dry, thick, and scaly from inflammation and barrier defects—explain clinical responses to the physical, chemical, and functional properties of psoriasis topical therapies.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59. https://doi.org/10.1016/j.jaad.2008.12.032.CrossRefPubMed

Assessment and management of psoriasis: NICE Clinical Guideline by the National Clinical Guidelines Centre at the Royal College of Physicians Oct 2012; pp 210–374.

van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Eur Acad Dermatol Venereol. 2015;29(10):2002–10. https://doi.org/10.1111/jdv.13150.CrossRefPubMedPubMedCentral

Vaidya TS, Alikhan A. Treatment satisfaction among patients with psoriasis at a large academic center: an observational study. [Published online ahead of print September 27, 2016]. J Dermatol Treat https://doi.org/10.1080/09546634.2016.1240865.

Finch T, Shim TN, Roberts L, Johnston O. Treatment satisfaction among patients with moderate-to-severe. J Clin Aesthet Dermatol. 2015;8(4):26–30.PubMedPubMedCentral

• Oda DC, de Korte J, Sprangers MAG, de Rie M, Smets EMA. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Brit J Dermal. 2013;169(2). An excellent study on patient satisfaction.

•• Alinia H, Moradi TS, Smith JA, et al. Long term adherence to topical psoriasis treatment can be abysmal: a 1-year randomised intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–64. https://doi.org/10.1111/bjd.15085. A unique methodology lasting one year on patient adherence. CrossRefPubMed

•• Feldman SR, Goffe B, Rice G, Mitchell M, Kaur M, Roberson D, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. An Health Drug Benefits. 2016;9(9):504–13. A U.S. multicenter study that underscores why holistic management is needed.

•• Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81. https://doi.org/10.1016/j.jaad.2013.12.018. A multi-country survey also underscoring why holistic management is needed. CrossRefPubMed

10.

•• Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physical results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87–97. https://doi.org/10.1007/s40257-015-0169-x. The US perspective on the same subject. CrossRefPubMed

11.

•• Wu JJ, Lynde CW, Kleyn CE, Iversen L, van der Walt JM, Carvalho A, et al. Identification of key research needs for topical therapy treatment of psoriasis-a consensus paper by the International Psoriasis Council. J Eur Acad Dermatol Venereol. 2016;30(7):1115–9. https://doi.org/10.1111/jdv.13614. More on the same subject of holistic management underscoring its importance. CrossRefPubMed

12.

Thaci D, Augustin M, Krutmann J, Luget T. Importance of basic therapy in psoriasis. J Dtsch Dermatol Ges. 2015;13(5):415–8. https://doi.org/10.1111/ddg.12615.PubMed

13.

Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235–45. https://doi.org/10.4103/2229-5178.209622. ReviewCrossRefPubMedPubMedCentral

14.

Vasilopoulos Y, Walters K, Cork MJ, Duff GW, Sagoo GS, Tazi-Ahnini R. Association analysis of the skin barrier gene cystatin a at the PSORS5 locus in psoriatic patients: evidence for interaction between PSORS1 and PSORS5. Eur J Hum Genet. 2008;16(8):1002–9. https://doi.org/10.1038/ejhg.2008.40.CrossRefPubMed

15.

Huffmeier U, Bergboer JG, Becker T, et al. Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Invest Dermatol. 2010;130(4):979–84. https://doi.org/10.1038/jid.2009.385.CrossRefPubMed

16.

Riveira-Munoz E, He SM, Escaramis G, et al. Meta-analysis confirms the LCE3C and LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol. 2011;131(5):1105–9. https://doi.org/10.1038/jid.2010.350.CrossRefPubMed

17.

Zhang XJ, Huang W, Yang S, Sun LD, Zhang FY, Zhu QX, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet. 2009;41(2):205–10. https://doi.org/10.1038/ng.310.CrossRefPubMed

18.

Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985–90. https://doi.org/10.1038/ng.694.CrossRefPubMedPubMedCentral

19.

Okada Y, Han B, Tsoi LC, Stuart PE, Ellinghaus E, Tejasvi T, et al. Fine mapping major histocaompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95(2):162–72. https://doi.org/10.1016/j.ajhg.2014.07.002.CrossRefPubMedPubMedCentral

20.

Yin X, Low HQ, Wang L, Li Y, Ellinghaus E, Han J, et al. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun. 2015;6:6916. https://doi.org/10.1038/ncomms7916.CrossRefPubMedPubMedCentral

21.

•• Puig L, Julia A, Marsai S. The pathogenesis and genetics of psoriasis. Actas Dermosifiliogr. 2014;105(6):535–45. https://doi.org/10.1016/j.ad.2012.11.006. New findings on psoriasis genesis in regards to the skin barrier. CrossRefPubMed

22.

•• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. https://doi.org/10.1016/j.jaut.2015.07.008. An excellent immuno-pathogenetic model of psoriasis. CrossRefPubMedPubMedCentral

23.

•• Stawczyk-Macieja M, Aneta Szczerkowska-Dobosz A, Rębała K, Dorota Purzycka-Bohdan D. Genetic background of skin barrier dysfunction in the pathogenesis of psoriasis vulgaris. Postepy Dermatol Alergol. 2015; XXXII;2(2):123–6. https://doi.org/10.5114/pdia.2014.44003. Recent study on the barrier in psoriasis.

24.

•• Ye L, Lv C, Man G, Song S, Elias PM, Man M-Q. Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol. 2014;134(11):2843–6. https://doi.org/10.1038/jid.2014.205. A good clinical translation of the basic studies done on the barrier in psoriasis. CrossRefPubMedPubMedCentral

25.

•• Wooi NK, Lau WM. Skin deep: the basics of human skin structure and drug penetration. In: Dragicevie N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Springer: Berlin; 2015. p. 3–11. An excellent basis for understanding natural oils and their effects on the skin.

26.

Verallo-Rowell VM, Katalbas SS, Pangasinan JP. Natural (mineral, vegetable, coconut, essential) oils and contact dermatitis. Curr Allergy Asthma Rep. 2016;16(7):51. https://doi.org/10.1007/s11882-016-0639-9.CrossRefPubMed

27.

Ali B, Al-Wabel NA, Shams S, Abamad A, Khan AS, Anwar F. Review article essential oils used in aromatherapy: a systematic review. Asian Packag J Trop Biomed. 2015;5(8):601–11. https://doi.org/10.1016/j.apjtb.2015.05.007.CrossRef

28.

de Groot AC, Schmidt E. Review essential oils, part I: introduction. Dermatitis. 2016;27(2):39–42. https://doi.org/10.1097/DER.0000000000000175.CrossRefPubMed

29.

Rawlings AV, Lombard KJ. A review on the extensive skin benefits of mineral oil. Int J Cosmet Sci. 2012:34–511.

30.

•• Enig MG. Know your fats: the complete primer for understanding the nutrition of fats, oils, and cholesterol .Chapter 4. The many sources of Fats and Oils. Bethesda Press; 2002. pp 113–152. Basic and Simple on the chemistry of fats.

31.

Fluhr JW, Darlensi R, Surber C. Glycerol and the skin holistic approach to its origin and functions. Br J Dermatol. 2008;159(1):23–4. https://doi.org/10.1111/j.1365-2133.2008.08643.x.CrossRefPubMed

32.

Verallo-Rowell VM. Rx: Coconuts! (The Perfect Health Nut), XLibris Philadelphia. 2005;25–90.

33.

• Mack Correa CM, Mao G, Saad P, Flach CR, Mendelsohn R, Walters RM. Molecular interactions of plant oil components with stratum corneum lipids correlate with clinical measures of skin barrier function. Exp Dermatol. 2014;23(1):39–4. https://doi.org/10.1111/exd.12296. A study on how natural oils become incorporated into the epidermal cells.CrossRefPubMed

34.

Madison KC, Howard EJ. Ceramides are transported through the Golgi apparatus in human keratinocytes in vitro. J Invest Dermatol. 1996;106(5):1030–5. https://doi.org/10.1111/1523-1747.ep12338596.CrossRefPubMed

35.

Schroeter A, Eichener A, Mueller J, Neubert RHH. The importance of stratum corneum lipid organization for proper barrier function, in Percutaneous Penetration Enhancers Chemical methods in penetration enhancement. Drug manipulation strategies and vehicle effects. Eds Dragicevic N, Maibach HI. 2015;19–38.

36.

Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetrate of chemical compounds and drugs. Exp Dermatol. 2000;9(30):165–9. https://doi.org/10.1034/j.1600-0625.2000.009003165.x.CrossRefPubMed

37.

Hussain A, Singh S, Sharma D, Webster TJ, Shafaat K, Faruk A. Elastic liposomes as novel carriers: recent advances in drug delivery. Int J Nanomedicine. 2017;12:087–5108.CrossRef

38.

Kumar PKP, Krishna AGG. Physicochemical characteristics of commercial coconut oils produced in India. Grass Y Aceites. 2015;66(1):e062ISSN-L:0017–3495.

39.

Anastopoulous G, Zannikou Y, Stournas S, Kalligeros S. Transesterification of vegetable oils with ethanol and characterisation of the key fuel properties of ethyl esters. Energies. 2009;2(2):362–76. https://doi.org/10.3390/en20200362.CrossRef

40.

•• Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27. https://doi.org/10.1007/s00281-015-0539-8. New and well written on therapy based on immunopathogenesis. CrossRefPubMed

41.

Ali SM, Yosipovitch G. Skin pH: from basic science to basic skin care. Acta Dermatol Venereol. 2013;93(3):261–7. https://doi.org/10.2340/00015555-1531.CrossRef

42.

Serafini A. Beitrag zum experimentellen Studium der Desinfectionsfahigkeit gewohnlichseifen. Arch Hyg. 1898;33:369–98.

43.

Konradi D. Uber die bactericide Wirkung der Seifen. Arch Hyg. 1902;44:101–12.

44.

Reichenbach H. Die desinfizierenden Berstandteile der Seifen. Zeitschr Hyg. 1908;9:296–316.

45.

Ferri M, Ranucci E, Romagnoli P, Giaconni V. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857–76. https://doi.org/10.1080/10408398.2015.1077192.CrossRefPubMed

46.

Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP. Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother. 1971;2:23–8.CrossRef

47.

•• Thormar H, Hilmarsson H, Bergsson G. Antimicrobial lipids: role in innate immunity and potential use in prevention and treatment of infections. In: Méndez-Vilas A, editor. Microbial pathogens and strategies for combating them: science, technology and education, vol. 3. Badajoz: Formatex Research Center; 2013. p. 1474–88. This is an important information source on the antimicrobial effects of natural oils.

48.

Desbois AP, Smith VJ. Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl Microb Biotechnol. 2010;85(6):1629–42. https://doi.org/10.1007/s00253-009-2355-3.CrossRef

49.

Heerklotz H. Interactions of surfactants with lipid membranes. Q Rev Biophys. 2008;41(3-4):205–64. https://doi.org/10.1017/S0033583508004721.CrossRefPubMed

50.

Hammer KA, Carson CF. Antibacterial and antifungal activities of essential oils. In: Lipids and Essential oils as antimicrobial agents. Hoboken: John Wiley & Sons, Ltd; 2011. p. 255–306.

51.

• Jackman JA, Yoon BK, Li D, Cho NJ. Nanotechnology formulations for antibacterial free fatty acids and monoglycerides. Molecules. 2016;21(3):305. https://doi.org/10.3390/molecules21030305. New and very futuristic uses for lipids. CrossRefPubMed

52.

• Szepietowski JC, Reich A. Mini review pruritus in psoriasis: an update. E J Pain. 2015;20(1):41–6. https://doi.org/10.1002/ejp.768. New studies on neurogenic basis for the itching in psoriasis.

53.

•• Norlén L. Molecular structure and function of the skin barrier. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Berlin: Springer; 2015. p. 39–42. This continues with more basic knowledge about the barrier layer of the skin as background to understanding natural oils and their effects on the barrier.

54.

Roussel L, Abdayem R, Gilbert E, Pirot F, Haftek M. Influence of excipients on two elements of the stratum corneum barrier: intercellular lipids and epidermal tight junctions. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetraten enhancement. Berlin: Springer; 2015. https://doi.org/10.1007/978-3-662-45013-0_7.

55.

•• Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms, and clinical relevance. Biochem Biophys Acta. 2014. This continues the understanding of pro- and antiinflammatory effects of fatty acids derived from natural oils.

56.

Gomez C, Candela LM, Lopez B, Kohen VL. Importance of a balanced omega6/omega3 ratio for the maintenance of health. Nutritional recommendations. Nutr Hosp. 2011;26(2):323–9.

57.

Baumann L. Olive oil Ch 14. In: Baumann L, editor. Cosmeceuticals and cosmetic ingredients. 1st ed. New York: McGraw-Hill; 2015. p. 37–40.

58.

mvo.nl/media/voedselveiligheid/codex_standard_named_vegetable_oils.pdf . Accessed 6 Nov 2017.

59.

Librado AS, Von Luigi MV. Phenolic-dependent anti-lipid perioxidative, antimodulatory and antioxidant activity of VCO in vitro. Int Food Res J. 2013;20

60.

Carocho M, Ferreira IC. A review on antioxidants, prooxidants, and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives. Food Chem Toxicol. 2013;51:15–25. https://doi.org/10.1016/j.fct.2012.09.021.CrossRefPubMed

61.

•• del Rosso JQ. Moisturizer and barrier repair formulations. In: Draelos ZD, editor. Cosmeceuticals. 3rd ed. Amsterdam: Elsevier Inc; 2016. p. 81–90. Excellent summary of what’s out there.

62.

•• Elias PM. Physiologic lipids for barrier repair in Ch 7. In: Draelos ZD, Dover JS, Alam M, editors. Cosmeceuticals. 3rd ed. Amsterdam: Elsevier; 2016. p. 49–54. This focuses on the lipids of the barrier and makes us understand how natural oils may be incorporated in it.

63.

• Agero LA, Verallo-Rowell VM. A ramdomized double-blind controlled trial comparing extra virgin coconut oil with mineral oil as a moisturiser for mild to moderate xerosis. Dermatitis. 2004;15(3):109–16. https://doi.org/10.2310/6620.2004.04006. Our first study on coconut oil as a moisturiser.CrossRefPubMed

64.

• Escuadro MO, Maano MMC, Dofitas BL. A randomzied assessor blinded controlled trial on the efficacy and safety of virgin coconut oil versus mineral oil as a therapeutic moisturiser for senile xerosis. Poster Presentation published in Abstracts American Contact Dermatitis Society Annual Meeting 2013. A second study ten years later.

65.

• Evangelista MTP, Casintahan MFS, Villafuerte LL. The effect of topical virgin coconut oil on SCORAD index, transepidermal water loss and skin capacitance in mild to moderate pediatric atopic dermatitis: a randomized double-blind clinical trial. Int J Dermatol. 2014;53(1):100–8. https://doi.org/10.1111/ijd.12339.CrossRefPubMed

66.

Abraham ERL, Verallo-Rowell VM, Baello BQ. Testing of lauricidin vs. isopropyl alcohol for antisepsis of cutaneous hand microbes to prevent infection. Phil J Microbiol Infect Dis. 2000;29(3):12–135.

67.

Abraham ERL, Verallo-Rowell VM. Safety and efficacy of monolaurin, a coconut extract vs. isopropyl alcohol in rinse-free hand antiseptic gels on MMC personnels hands and microbial isolates. J Phil Dermatol Soc. 2001;2:90–9.

68.

Carpo BG, Verallo-Rowell VM, Kabara J. Novel antibacterial activity of monolaurin compared with converntional antibiotics against organisms from skin infections:an in-vitro study. J Drugs Dermatol. 2007;6(10):981–8.

69.

Verallo-Rowell VM, Dillague KM, Sjah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008;19(6):308–15.PubMed

70.

Kim HO, Kim JH, Chung BY, Choi MG, Park CW. Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases. Exp Dermatol. 2014;23(4):278–81. https://doi.org/10.1111/exd.12350.CrossRefPubMed

71.

Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, et al. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol. 2006;126(6):1396–402. https://doi.org/10.1038/sj.jid.5700276.CrossRefPubMed

72.

Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar salicylic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol. 2014;59:57983.CrossRef

73.

Chiricozzi A, Pitocco R, Saraceno R, Nistico SP, Giunta A, Chimenti S. New topical treatments for psoriasis. Expert Opin Pharmacother. 2014;15(4):461–70. https://doi.org/10.1517/14656566.2014.875159.CrossRefPubMed

74.

Hollywood KA, Winder CL, Dunn WB, Xu Y, Broadhurst D, Griffiths CEM, et al. Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol BioSyst. 2015;11(8):2198–209. https://doi.org/10.1039/c4mb00739e.CrossRefPubMed

75.

Jacobi A, Mayer A, Augustin M. Keratolytics and emollients in the therapy of psoriasis. Dermatol Ther (Heidelb). 2015;5(1):1–18. https://doi.org/10.1007/s13555-015-0068-3.CrossRef

76.

Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:1–16. https://doi.org/10.1155/2012/561018.CrossRef

77.

Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2013; Issue 3. Art. No.: CD005028. https://doi.org/10.1002/14651858.CD005028.pub3.

78.

Reichrath J, Perez A, Müller SM, Chen TC, Kerber A, Bahmer FA, et al. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol. 1997;77(4):268–72.PubMed

79.

van de Kerkhof PCM. An update on topical therapies for mild-moderate psoriasis. Dermatol Clin. 2015;33(1):73–7. https://doi.org/10.1016/j.det.2014.09.006.CrossRefPubMed

80.

Prasad V, Chaurasia S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater Sci Eng C. 2017;79:168–76. https://doi.org/10.1016/j.msec.2017.05.036.CrossRef

81.

Koo J, Behnam SE, Behnam SM. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis. Expert Opin Pharmacother. 2003;4(12):2347–54. https://doi.org/10.1517/14656566.4.12.2347.CrossRefPubMed

82.

Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8–14. https://doi.org/10.2310/7750.2013.13059.PubMed

83.

Lapteva M, Mondon K, Möller M, Gurny R, Kalia YN. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001. https://doi.org/10.1021/mp400639e.CrossRefPubMed

84.

Gabriel D, Mugnier T, Courthion H, Kranidioti K, Karagianni N, Denis MC, et al. Improved topical delivery of tacrolimus: a novel composite hydrogel formulation for the treatment of psoriasis. J Control Release. 2016;242:16–24. https://doi.org/10.1016/j.jconrel.2016.09.007.CrossRefPubMed

85.

Wan T, Pan J, Long Y, Yu K, Wang Y, Pan W, et al. Dual roles of TPGS based microemulsion for tacrolimus: enhancing the percutaneous delivery and anti-psoriatic efficacy. Int J Pharm. 2017;528(1–2):511–23. https://doi.org/10.1016/j.ijpharm.2017.06.050.CrossRefPubMed

86.

Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. Expert Opin Pharmacother. 2017;18(1):1,115–21. https://doi.org/10.1080/14656566.2016.1269749.CrossRef

87.

Yamauchi P. DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis. Expert Rev Clin Immunol. 2016;13(2):85–91. https://doi.org/10.1080/1744666X.2017.1270756.CrossRefPubMed

88.

Efficacy and safety of calcipotriol plus hydrocortisone ointment compared with tacalcitol ointment in patients with psoriasis on the face and skin folds (NCT00640822). https://clinicaltrials.gov/ct2/show/results/NCT00640822?term=NCT00640822 . Updated October 21, 2013.

89.

Kivelevitch DN, et al. Emerging topical treatments for psoriasis. Expert Opin. Emerging Drugs. 2013;18(4).

90.

Rivera AM, Hsu S. Topical halobetasol propionate in the treatment of plaque psoriasis: a review. Am J Clin Dermatol. 2005;6(5):311–6. https://doi.org/10.2165/00128071-200506050-00004.CrossRefPubMed

91.

Dermipsor reports good results in DPS-101 Phase IIb study for plaque psoriasis [press release]. Evaluate website. http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=250042. Published October 15, 2007.

92.

Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10(11):1236–42.PubMed

93.

Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014;20:22608.PubMed

94.

Product candidates: targeting p-STAT3 for improved psoriasis treatment. Moleculin Web site. http://moleculin.com/product-candidates/mol4239

95.

Paired psoriasis lesion, comparative, study to evaluate MOL4239 in psoriasis (NCT01826201). https://clinicaltrials.gov/ct2/show/results/NCT01826201?term=NCT01826201 .... Updated December 22, 2014.

96.

Roblin D, Yosipovitch G, Boyce B, Robinson J, Sandy J, Mainero V, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95(5):542–8. https://doi.org/10.2340/00015555-2047.CrossRefPubMed

97.

Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45. https://doi.org/10.1111/bjd.12266.CrossRefPubMedPubMedCentral

98.

Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, et al. Treatment of plaque psoriasis with an ointment formulation of the janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16(1):15. https://doi.org/10.1186/s12895-016-0051-4.CrossRefPubMedPubMedCentral

99.

Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–64. https://doi.org/10.1016/j.jaad.2011.12.018.CrossRefPubMed

100.

Rafael A, Torres T. Topical therapy for psoriasis: a promising future, focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol. 2016;26(1):3–8. https://doi.org/10.1684/ejd.2015.2663.PubMed

101.

de la Brassinne M, Nikkels A. Psoriasis: state of the art 2013. Acta Clin Belg. 2013;68(6):433–41. https://doi.org/10.2143/ACB.3388.CrossRefPubMed

102.

Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized, double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516–21. https://doi.org/10.1111/j.1468-3083.2011.04332.x.PubMed

Titel: Review Update on Topical Therapy for Psoriasis
verfasst von: Vermén M. Verallo-Rowell
Stephanie S. Katalbas
Mara Therese P. Evangelista
Johannes F. Dayrit
Publikationsdatum: 19.02.2018
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 1/2018
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-018-0209-x

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Review Update on Topical Therapy for Psoriasis

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Evaluation of the Itchy Patient

A Review and Update of Phototherapy Treatment Options for Psoriasis

Update on Oral Therapy for Psoriasis

Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis

Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations

Update on Noninvasive Diagnostic Imaging and Management of Nonmelanoma Skin Cancer

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie